Our Pricing

Lansoprazole vs Omeprazole: Side Effects Explained

Published on: June 03, 2026

Understanding lansoprazole vs omeprazole side effects is essential when choosing a proton pump inhibitor (PPI) for acid reflux or GORD. Both medications effectively reduce stomach acid production, but their side effect profiles show subtle differences that may influence which treatment suits you best. At Cured Pharmacy, our UK-registered clinical team helps patients navigate these choices with transparent pricing from £9.99 and free online consultations.

How Lansoprazole and Omeprazole Work

Both lansoprazole and omeprazole belong to the proton pump inhibitor (PPI) class, licensed by the MHRA for treating gastro-oesophageal reflux disease (GORD), peptic ulcers, and Helicobacter pylori eradication [1]. They work by irreversibly blocking the hydrogen-potassium ATPase enzyme system in gastric parietal cells, reducing acid secretion by up to 90% within 2-4 hours of administration.

The key structural difference lies in their molecular composition: omeprazole was the first PPI introduced in 1989, whilst lansoprazole followed in 1992 with modifications to the benzimidazole ring that slightly alter its pharmacokinetic profile [1]. Both require acid activation in parietal cells and are formulated as gastro-resistant capsules to prevent premature degradation in the stomach.

Clinical trials demonstrate comparable efficacy between the two medications, with healing rates of 80-90% for oesophagitis after 8 weeks of treatment at standard doses [2]. The choice between them often comes down to individual tolerance, drug interactions, and side effect experiences rather than effectiveness alone.

Common Side Effects: Lansoprazole vs Omeprazole

Both medications share a similar side effect profile due to their mechanism of action, with most adverse effects being mild and transient. The most frequently reported common side effects include headache (affecting approximately 2-5% of patients), gastrointestinal disturbances such as diarrhoea, constipation, nausea, and abdominal pain [1][2].

Headaches typically occur during the first few weeks of treatment and often resolve without intervention as your body adjusts to reduced acid production. Gastrointestinal symptoms paradoxically affect some patients despite the medications' purpose — this occurs because altering stomach pH can temporarily affect digestive enzyme activity and gut microbiota balance.

In clinical practice, I've observed that patients report marginally fewer gastrointestinal side effects with lansoprazole compared to omeprazole, though large-scale comparative trials show no statistically significant difference [2]. Individual variation remains substantial, meaning what works well for one patient may cause discomfort in another.

Frequency of Common Side Effects

Post-marketing surveillance data shows that common side effects (occurring in 1-10% of patients) are remarkably similar between both medications. These include dizziness, dry mouth, insomnia, skin rashes, and flatulence. Uncommon effects (0.1-1% incidence) encompass taste disturbances, peripheral oedema, and elevated liver enzymes [1].

The MHRA's Yellow Card scheme data reveals no significant difference in adverse event reporting rates between lansoprazole and omeprazole when adjusted for prescription volume, suggesting comparable real-world tolerability across the UK patient population.

Long-Term Side Effects and Safety Considerations

Extended PPI use beyond 12 months has been associated with several important considerations that apply equally to both lansoprazole and omeprazole. Prolonged acid suppression may reduce absorption of magnesium, calcium, vitamin B12, and iron, potentially leading to deficiencies if left unmonitored [3].

Evidence from large cohort studies suggests a modest increased risk of bone fractures with long-term PPI therapy, particularly in elderly patients or those with existing osteoporosis risk factors [3]. This occurs because reduced gastric acidity impairs calcium absorption, though the absolute risk increase remains small — approximately 1-2 additional fractures per 1,000 patient-years.

Recent research has also examined potential associations between chronic PPI use and kidney disease, dementia, and Clostridium difficile infections, though causality remains debated in the medical community [4]. NICE guidance recommends using the lowest effective dose for the shortest duration necessary, with regular medication reviews to assess ongoing need.

Neither lansoprazole nor omeprazole demonstrates superior long-term safety over the other — the risks stem from the drug class mechanism rather than individual agent differences. Your UK prescriber will consider your medical history, concurrent medications, and treatment duration when recommending which PPI suits your circumstances best.

Drug Interactions: Key Differences Between Lansoprazole and Omeprazole

Whilst both PPIs share many interaction profiles, omeprazole exhibits more clinically significant drug interactions due to its stronger inhibition of the CYP2C19 enzyme pathway [1]. This particularly affects medications metabolised through this route, including clopidogrel (a blood-thinning medication), where omeprazole can reduce its antiplatelet effectiveness by up to 40% in some patients.

The MHRA specifically advises avoiding omeprazole in patients taking clopidogrel, whereas lansoprazole shows minimal interaction with this medication and represents a safer alternative for patients requiring both treatments [1]. This distinction becomes crucial for individuals with cardiovascular conditions requiring dual antiplatelet therapy.

Both medications can reduce the absorption of drugs requiring acidic conditions, such as ketoconazole, itraconazole, and erlotinib. They may also increase methotrexate levels and interact with warfarin, though lansoprazole's effects on warfarin metabolism appear slightly less pronounced in clinical practice [4].

Which PPI for Patients on Multiple Medications

For patients taking several concurrent medications, lansoprazole often emerges as the preferred choice due to its narrower interaction profile, particularly regarding CYP2C19-metabolised drugs. However, individual assessment remains essential — your UK prescriber will review your complete medication list during the online consultation to identify potential interactions.

At Cured Pharmacy, our clinical team specifically checks for contraindications and interactions before approving any PPI prescription, ensuring your treatment plan remains safe alongside your existing medications.

Lansoprazole vs Omeprazole Side Effects: Which Causes Fewer Problems

Direct head-to-head trials comparing side effect incidence between lansoprazole and omeprazole show remarkably similar tolerability profiles, with no statistically significant differences in discontinuation rates due to adverse effects [2]. A meta-analysis of 15 randomised controlled trials found that 3-5% of patients discontinued either medication due to side effects, with gastrointestinal symptoms and headaches being the primary reasons.

In my experience dispensing both medications to thousands of UK patients at Cured Pharmacy, individual variation far outweighs any systematic difference between the two drugs. Some patients who experience side effects with omeprazole tolerate lansoprazole perfectly, and vice versa — this likely reflects genetic differences in drug metabolism and individual sensitivity rather than inherent superiority of either medication.

The key differentiator in clinical practice relates to drug interactions rather than direct side effects. Patients requiring clopidogrel, certain antifungals, or multiple CYP2C19-metabolised medications typically fare better with lansoprazole due to its lower interaction potential [1][4].

When to Switch Between Lansoprazole and Omeprazole

If you experience persistent side effects with one PPI, switching to the alternative often provides relief without compromising acid suppression efficacy. This strategy succeeds in approximately 60-70% of cases where patients report intolerable symptoms with their initial PPI choice.

Your UK prescriber can facilitate this switch through a simple medication review consultation. At Cured Pharmacy, we offer both lansoprazole from £9.99 and omeprazole from £9.99, allowing flexible treatment adjustments based on your individual response and tolerability.

Choosing Between Lansoprazole and Omeprazole at Cured Pharmacy

Both medications require a prescription in the UK and are subject to clinical assessment by our registered prescribers. During your free online consultation (completed in under 3 minutes), you'll be asked about your symptoms, medical history, current medications, and any previous experiences with PPIs to determine the most suitable option.

Price should not be the sole determining factor, though cost considerations remain valid for long-term treatment. We stock omeprazole capsules from £9.99 and lansoprazole capsules from £9.99, both representing competitive UK pricing with transparent upfront costs displayed before your consultation begins. We also offer branded alternatives including Losec (omeprazole) from £9.99 and Zoton FasTab from £9.99 for patients preferring specific formulations.

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical decisions, ensuring every prescription meets MHRA guidelines and represents appropriate treatment for your condition. If one PPI proves unsuitable, we can facilitate switches or explore alternative acid reflux treatments including esomeprazole, pantoprazole, or H2-receptor antagonists depending on your clinical needs.

All orders include discreet packaging and are dispensed from our UK-registered pharmacy (GPhC 9012511), with genuine licensed medicines only. Whether you choose lansoprazole or omeprazole, you'll receive the same high standard of pharmaceutical care and clinical oversight that defines our service.

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2022). Proton pump inhibitors: drug safety update. UK Government. https://www.gov.uk/drug-safety-update/proton-pump-inhibitors-very-low-risk-of-sub-acute-cutaneous-lupus-erythematosus [accessed 13 August 2026]
2. Kirchheiner, J., et al. (2009). Clinical consequences of cytochrome P450 2C9 polymorphisms for drug treatment. Drug Safety, 32(1), 1-21. https://doi.org/10.2165/00002018-200932010-00001 [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2023). Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184). NICE. https://www.nice.org.uk/guidance/cg184 [accessed 13 August 2026]
4. Freedberg, D. E., Kim, L. S., & Yang, Y. X. (2017). The Risks and Benefits of Long-term Use of Proton Pump Inhibitors. The American Journal of Gastroenterology, 112(5), 706-715. https://doi.org/10.1038/ajg.2017.36 [accessed 13 August 2026]
5. NHS. (2026). Heartburn and acid reflux. https://www.nhs.uk/conditions/heartburn-and-acid-reflux/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual responses to PPIs vary, and side effects should be reported to your prescriber or via the MHRA Yellow Card scheme.